Engene released additional pivotal‑cohort data for detalimogene voraplasmid, a nonviral gene therapy for high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer with carcinoma‑in‑situ. The amended protocol and expanded dataset continued to meet study endpoints and supported the company’s plan to file a biologics license application next year. The market reacted strongly—shares jumped after the data tranche—highlighting investor appetite for regenerative and gene‑based approaches in urologic oncology. Sponsors and regulators will watch durability, safety, and real‑world feasibility as Engene advances its BLA timeline.